EP Patent

EP2216021A1 — Pharmaceutical composition for treating overactive bladder

Assigned to Astellas Pharma Inc · Expires 2010-08-11 · 16y expired

What this patent protects

[Problems] To provide a pharmaceutical composition which is useful as a therapeutic agent for overactive bladder. [Means for solution] A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceut…

USPTO Abstract

[Problems] To provide a pharmaceutical composition which is useful as a therapeutic agent for overactive bladder. [Means for solution] A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof and (3R)-quinuclidin-3-yl (1S)-1-pbenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular a pharmaceutical composition for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and/or urinary incontinence

Drugs covered by this patent

Patent Metadata

Patent number
EP2216021A1
Jurisdiction
EP
Classification
—
Expires
2010-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.